The ability of interleukin-6 (IL-6) to modulate immune parameters and
mesangial cell function suggests a role for this cytokine in the devel
opment of autoimmune glomerulonephritis. This hypothesis was tested in
6-month-old female (NZBxNZW)F-1 mice that were administered recombina
nt human IL-6 (rhIL-6) (50 and 250 mu/kg s.c.) for 12 weeks, resulting
in an accelerated and severe form of membranoproliferative glomerulon
ephritis associated with marked upregulation of mesangial major histoc
ompatibility complex class II antigen and glomerular ICAM-1 expression
. To distinguish direct effects of rhIL-6 on the renal mesangium from
those mediated through the immune system, (NZBxNZW)F-1 mice were immun
osuppressed with cyclosporin. Immunosuppression by cyclosporin inhibit
ed the development by cyclosporin inhibited the development of glomeru
lonephritis, decreased class II antigen expression, and abrogated IL-6
-mediated effects. Administration of neutralizing anti-IL-6 antibody h
ad no effect on the spontaneous development of glomerulonephritis in (
NZBxNZW)F-1 mice. This finding, together with undetectable IL-6 serum
levels, makes a pathogenetic role of endogenously produced IL-6 in thi
s disease model unlikely. In contrast to (NZBxNZW)F-1 mice, parental N
ZW or BALB/c mice given high doses of rhIL-6 (500 mu g/kg) or recombin
ant murine IL-6 (100 mu g/kg) daily for 4 weeks failed to develop morp
hological or biochemical evidence of glomerulonephritis. Induction of
acute phase proteins, anemia, thrombocytosis, and induction of renal c
lass II antigen confirmed the biological activity of IL-6 in these mic
e. In conclusion, while non-nephritogenic in normal mice, IL-6 acceler
ates the development of the genetically determined glomerulonephritis
of (NZBxNZW)F-1 mice through effects mediated by a modulated immune sy
stem. Since neutralizing IL-6 antibody treatment did not prevent the d
evelopment of glomerulonephritis, it is unlikely that increased IL-6 p
roduction plays a role in the pathogenesis of lupus nephritis.